CDK4 and atrial fibrillation: Abemaciclib, palbociclib, and ribociclib are three CDK4/6 inhibitors approved by the US Food and Drug Administration that are overall well tolerated and safe from a cardiovascular standpoint but they have been associated with increased risk of hypertension, heart failure, and AF [40].